✦ LIBER ✦

Mesothelin is a biomarker of tumor aggressiveness and therapy response in malignant pleural mesothelioma (MPM)

✍ Scribed by Elliot L. Servais; Christos Colovos; Kei Suzuki; Marissa Velez; Luis Rodriguez; Camelia Sima; Valerie W. Rusch; Michel Sadelain; Prasad S. Adusumilli

Book ID: 113679935
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 91 KB
Volume: 211
Category: Article
ISSN: 1072-7515
DOI: 10.1016/j.jamcollsurg.2010.06.087

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

445 CD157 is a Novel Prognostic Marker o

445 CD157 is a Novel Prognostic Marker of Malignant Pleural Mesothelioma Involved in the Control of Tumor Aggressiveness

✍ A. Giacomino; S. Morone; R. Parrotta; N. Lo Buono; I. Rapa; L. Righi; M. Volante 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 52 KB

133 mTOR is a druggable molecule in Mali

133 mTOR is a druggable molecule in Malignant Pleural Mesothelioma targeted therapy: antiproliferative effect of sorafenib and everolimus in preclinical models

✍ Y. Pignochino; S. Inghilleri; M. Zorzetto; M. Luisetti; P. Morbini; M. Aglietta; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Phase 1 study of the antimesothelin immu

Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen

✍ Hassan, Raffit; Sharon, Elad; Thomas, Anish; Zhang, Jingli; Ling, Alexander; Mie 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 555 KB

Combined regimen of cisplatin (CDDP), ad

Combined regimen of cisplatin (CDDP), adriamycin (ADM) and a-2b interferon (IFN) in the treatment of advanced malignant pleural mesothelioma (MPM): A phase II multicenter trial of the Italian Group on Rare Tumors and Italian Lung Cancer Task Force (FONICAP)

✍ Santoro, A; Tixi, L; Soto Parra, H.J; Ardizzoni, A; Latteri, F; Bretti, S; Gravi 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 113 KB

Combination chemotherapy with Cisplatin

Combination chemotherapy with Cisplatin (CDDP) and Adriamycin (ADM) plus immunotherapy with interferon (IFN) alfa-2b in malignant pleural mesothelioma (MPM): results of a phase II trial of the Italian Group on Rare Tumors (GITR) and Italian Lung Cancer Task Force (FONICAP)

✍ Parra, H.Soto; Bretti, S.; Ardizzoni, A.; Tixi, L.; Latteri, F.; Gravina, A.; Li 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 167 KB